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Background: Experimental and clinical studies have suggested that remifentanil probably causes acute tolerance or 
postinfusion hyperalgesia. This study was designed to confirm whether remifentanil given during propofol anesthesia 
induced postoperative pain sensitization, and we wanted to investigate whether pregabalin could prevent this 
pronociceptive effect.
Methods: Sixty patients who were scheduled for total abdominal hysterectomy were randomly allocated to receive (1) 
a placebo as premedication and an intraoperative saline infusion (control group), (2) a placebo as premedication and 
an intraoperative infusion of remifentanil at a rate of 3-4 ng/ml (remifentanil group), or (3) pregabalin 150 mg as 
premedication and an intraoperative infusion of remifentanil at a rate of 3-4 ng/ml (pregabalin-remifentanil group). 
Postoperative pain was controlled by titration of fentanyl in the postanesthetic care unit (PACU), followed by patient-
controlled analgesia (PCA) with fentanyl. The patients were evaluated using the visual analogue scale (VAS) for pain 
scores at rest and after cough, consumption of fentanyl, sedation score and any side effects that were noted over the 
48 h postoperative period.
Results: The fentanyl titration dose given in the PACU was significantly larger in the remifentanil group as compared 
with those of the other two groups. At rest, the VAS pain score in the remifentanil group at 2 h after arrival in the 
PACU was significantly higher than those in the other two groups.
Conclusions: The results of this study show that remifentanil added to propofol anesthesia causes pain sensitization 
in the immediate postoperative period. Pretreatment with pregabalin prevents this pronociceptive effect and so 
this may be useful for the management of acute postoperative pain when remifentanil and propofol are used as 
anesthetics. (Korean J Anesthesiol 2011; 60: 198-204)
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Introduction
    Opioids are the main analgesics that are used for treating 
moderate to severe pain. However, many studies have suggested 
that they paradoxically result in postinfusion hyperalgesia and 
tolerance [1,2]. Remifentanil is an ultra short-acting μ-opioid 
receptor agonist that is commonly used to supplement general 
anesthesia. Some previous studies have failed to confirm [3,4], 
remifentanil causes a similar phenomenon after intraoperative 
infusion [5-7]. A recent study showed that previous exposure 
to remifentanil enhanced the mechanical hyperalgesia after a 
second surgery, and those authors suggested that preventive 
measures are needed to avoid latent sensitization in future 
surgeries [8].
    Opioid-induced pronociceptive effects are thought to result 
from the central and peripheral nervous system sensitization 
and they share the same mechanisms with that of the 
hyperalgesia associated with nerve injury [9,10]. This suggests 
that preemptive treatment with drugs that are effective for the 
management of neuropathic pain may prevent or reduce the 
pain sensitization induced by opioids.
    Pregabalin is a 3-substituted analogue of γ-amino butyric 
acid, and it was developed as a new-generation antiepileptic 
drug with fewer side effects. It has been approved for the 
treatment of neuropathic pain and anxiety disorder [11,12]. 
It has been shown to reduce hyperalgesia and allodynia in 
a preclinical model [13,14]. Gabapentin, which is a close 
structural relative of pregabalin and it has a similar mechanism 
of action, has been documented to prevent the development of 
tolerance and hyperalgesia elicited by opioids in animal model 
studies [15,16]. However, well-designed clinical studies on the 
effect of gabapentinoids for the prevention of opioid-induced 
pain sensitization have not yet been conducted. The present 
study was designed to test the hypothesis that intraoperative 
remifentanil infusion during propofol anesthesia induced 
postoperative pain sensitization as indicated by a higher pain 
score or a larger fentanyl dose is needed to achieve satisfactory 
analgesia and that preemptive treatment with pregabalin could 
prevent this pain sensitization.
Materials and Methods
    After receiving ethical committee approval, written informed 
consent was obtained from 60 ASA physical status I-II patients 
who were treated at our hospital. All of them were scheduled 
for non-malignant total abdominal hysterectomy with a 
supravaginal, horizontal approach under general anesthesia. 
The exclusion criteria were if patients had more than a 35 kg/
m
2 body mass index, the inability to use PCA, contraindications 
to any of drugs used in the study and a history of chronic pain, 
opioids use within 3 months before surgery, drug or alcohol 
addiction and kidney dysfunction.
    Before the study began, the patients were randomly allocated 
according to a computer generated random number sequence 
into one of three groups: (1) the control group in which the 
patients were given an identical-looking placebo orally as 
premedication and an intraoperative normal saline infusion, 
(2) the remifentanil group in which the patients were given 
an identical-looking placebo orally as premedication and an 
intraoperative infusion of remifentanil at a rate of 3-4 ng/
ml, or (3) pregabalin-remifentanil group in which the patients 
were given pregabalin 150 mg orally as premedication and 
intraoperative infusion of remifentanil at a rate of 3-4 ng/ml.
    The evening before surgery, the patients were instructed 
about the use of a PCA device (Accumate 1000
Ⓡ, Woo Young 
Medical, Korea), a four point verbal rating scale for pain (0 = 
no pain, 1 = slight and tolerable pain, 2 = moderate pain, 3 = 
severe pain) and a 100-mm VAS for pain (0 = no pain to 100 = 
worst imaginable pain). One hour before surgery, the patients 
received pregabalin 150 mg or an identical-looking placebo 
orally as premedication. Before the induction of anesthesia, a 
nurse who was not participating in the investigation prepared 
remifentanil or normal saline solution syringes. The personnel 
involved in the patient management and data collection did not 
know the group assignment.
    Upon the patients’ arrival in the operating room, the patients 
were monitored by pulse oximetry, electrocardiography and 
noninvasive blood pressure (BP). Anesthesia was induced 
with propofol at an initial target-effect site concentration of 
5 μg/ml and remifentanil at a target-effect site concentration 
of 4 ng/ml (Orchestra
Ⓡ, Fresenius Vial, France). After loss of 
consciousness, the patients received a bolus of vecuronium 1.2 
mg/kg and then they were ventilated to obtain normocapnia 
with 50% N2O in oxygen.
    General anesthesia was maintained with a continuous infusion 
of propofol (a target-effect site concentration of 2-6 μg/ml), and 
this was titrated to maintain the Bispectral Index (BIS) between 
45 and 55. The target remifentanil concentration was adjusted 
between 3 ng/ml and 4 ng/ml, according to the patient’s vital 
signs. Twenty minutes before the anticipated end of surgery, 
remifentanil or saline was discontinued and all the patients 
received an injection of IV fentanyl 25 μg and ondansetron 
4 mg. During the closure of skin, the propofol and N2O were 
discontinued and the neuromuscular block was antagonized 
with glycopyrrolate 0.4 mg and pyridostigmine 15 mg. The 
endotracheal tube was removed when the patient recovered 
consciousness and spontaneous respiration. The total doses 
of propofol and remifentanil infused during the anesthesia 
and the duration of anesthesia and surgery were recorded. The 
times from the end of surgery to awakening (opening their eyes 200 www.ekja.org
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on a verbal command), recovery of spontaneous ventilation 
and tracheal extubation were also noted.
    The patients were transferred to the PACU and they remained 
in the unit for at least 1 h. Postoperative pain was initially 
controlled by titration of IV fentanyl, which was given at every 
3 minute interval in 25 μg increments until the verbal rating 
pain score was less than 2. Fentanyl titration was discontinued 
if the patient had peripheral oxygen saturation less than 92%, 
a respiration rate less than 10 breaths/min or a sedation score 
greater than 4. Subsequently, analgesia was continued with 
PCA that delivered fentanyl 0.3 μg/kg as an IV bolus, with a 
lockout interval of 5 min and no background infusion for 48 h. 
The sedation score was assessed by the Ramsay sedation scale 
(1 = anxious and agitated or restless, or both, 2 = cooperative, 
oriented and tranquil, 3 = responds to command only, 4 = 
asleep, but has a brisk response to a light glabellar tap or a 
loud auditory stimulus, 5 = asleep, but has a sluggish response 
to a light glabellar tap or loud auditory stimulus, 6 = asleep, 
no response). The patients were evaluated for the VAS pain 
scores (at rest and after cough), heart rate (HR), BP, sedation 
score, respiration rate and the fentanyl consumption by PCA 
over the 48 h postoperative period. The fentanyl titration dose 
was the amount of fentanyl needed to obtain adequate pain 
relief (a verbal rating pain sore less than 2) in the PACU and 
this did not include the intraoperative fentanyl bolus. The 
cumulative fentanyl consumption was the amount of fentanyl 
administrated by the PCA device, with excluding titration. The 
occurrence of any side effects such as nausea, vomiting, dry 
mouth, pruritus, somnolence, dizziness, headache and swelling 
of limbs was recorded during the study period. Hypotension 
(mean BP < 60 mmHg) or bradycardia (HR < 45 beats/min) 
was treated with 5 mg ephedrine or atropine 0.5 mg. The 
patients were telephoned on the first and third month after 
their discharge from the hospital and they were interviewed to 
inquire about their present pain score and the occurrence of 
any side effects.
    The amount of fentanyl given by titration in the PACU to 
control the acute postoperative pain was considered the primary 
outcome of our study. From our initial pilot observations, we 
estimated the standard deviation within each group to be 
approximately 90 and the effect size was equal to approximately 
0.42. For estimating the priori sample size, we used G*power 
software, version 3.0.10 for Windows and nineteen patients in 
each treatment group would be required when the α error was 
presumed to be 0.05. Post hoc calculation of the achieved power 
was 0.81. Based on our own experience using this experimental 
setting, we expected a dropout rate of 5%. Therefore, the total 
number of patients was set at 60 persons. The demographic 
characteristics, the duration of surgery and anesthesia, the 
fentanyl consumption and the pain VAS scores at each time 
point were compared among the three groups using one-way 
analysis of variance. For post hoc comparisons, we used the 
Turkey test, as needed. The Fisher’s exact test or χ
2 test was 
used for categorical variables. The hemodynamic variables 
were analyzed with two-way analysis of variance for repeated 
measures. For data analysis, we used SPSS software (Version 
14.0 for Windows) and statistical significance throughout the 
study was defined as P value < 0.05.
Results
    All the patients were able to complete the study and the 
groups were comparable with respect to the demographic 
characteristics, the duration of surgery and anesthesia, the total 
consumption of propofol and remifentanil and the recovery 
times (Table 1).
    The fentanyl titration dose given in the PACU was significantly 
different between the groups (F = 7.744, P = 0.001) (Fig. 1). Post 
hoc analysis demonstrated that the remifentanil group required 
the greatest amount of fentanyl (P = 0.002 for the control group, 
Table 1. Demographic Characteristics and the Perioperative Data 
Variable Control (n = 20) Remifentanil (n = 20) Pregabalin-Remifentanil (n = 20)
Age (yr)
Weight (kg)
Height (cm)
ASA (I/II)
Duration of surgery (min)
Duration of anesthesia (min)
Propofol dose (mg/min)
Remifentanil dose (μg/min)
Recovery time (min)
    Eye opening
    Spontaneous respiration
    Extubation
44.8 ± 5.4
62.5 ± 6.9
159.0 ± 5.1
15/5
122.3 ± 35.0
147.0 ± 33.3
7.1 ± 1.5
6.3 ± 4.3
2.7 ± 2.1
7.0 ± 4.5
46.0 ± 5.2
61.0 ± 9.5
155.7 ± 4.7
17/3
120.3 ± 43.2
145.0 ± 40.7
6.2 ± 1.3
6.5 ± 1.5
4.3 ± 3.7
2.0 ± 1.6
4.7 ± 3.9
46.2 ± 6.6
60.2 ± 7.9
157.4 ± 5.9
17/3
134.4 ± 27.1
158.0 ± 27.3
6.3 ± 1.4
6.3 ± 1.7
6.3 ± 3.9
3.8 ± 2.8
7.0 ± 3.7
Values are presented as mean ± SD or the number of patients. 201 www.ekja.org
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P = 0.009 for the pregabalin-remifentanil group). No significant 
differences between the three groups were found for fentanyl 
consumption by PCA over the 48 h postoperative period (Table 2).
    The VAS scores at rest (Fig. 2A) were similar in the three 
groups during the 48 h postoperative period except at 2 h 
after arrival at the PACU at which time the VAS score in the 
remifentanil group (36.5 ± 14.6 mm) was significantly higher 
than those in the control group (26.5 ± 9.3 mm, P = 0.016) and 
the pregabalin-remifentanil group (27.0 ± 8.0 mm, P = 0.023). 
The VAS scores after cough of remifentanil group (Fig. 2B) at 
2 h after arrival at the PACU were higher than those of other 
groups, although there were no significant differences between 
the groups (P = 0.109 for the control group, P = 0.112 for the 
pregabalin-remifentanil group).
    There were no significant differences in the incidence of side 
effects throughout the study among the three groups (Table 3). 
Two patients in the pregabalin-remifentanil group during the 
operation experienced bradycardia (45 beats/min) without 
hypotension, but the hemodynamic variables throughout 
Table 2. Fentanyl Consumption
Control (n = 20) Remifentanil (n = 20) Pregabalin-Remifentanil (n = 20) P
By titration in PACU (µg) 
By PCA (µg)
    2 h
    3 h
    6 h
    24 h
    48 h
133.8 ± 87.8
108.5 ± 59.5
150.0 ± 73.4
231.3 ± 120.1
413.3 ± 256.8
651.6 ± 367.5
227.5 ± 88.1*
138.8 ± 73.6
211.9 ± 122.5
307.7 ± 171.9
568.6 ± 336.4
756.5 ± 502.4
148.8 ± 64.6
127.4 ± 57.6
174.6 ± 78.8
278.8 ± 130.4
560.0 ± 234.2
812.3 ± 395.4
0.001
0.326
0.121
0.239
0.547
0.179
Values are presented as mean ± SD. PCA: patient-controlled analgesia, PACU: postanesthetic care unit. *P < 0.05, when comparing the 
remifentanil group with the control group and the pregabalin-remifentanil group.
Fig. 1. The fentanyl titration dose in the postanesthetic care unit. 
Values are presented as mean ± SD. *P < 0.05, when comparing 
the remifentanil group with the control group and the pregabalin-
remifentanil group.
Fig. 2. The visual analogue scale (VAS) pain scores at rest (A) and after cough (B) over the 48 h postoperative period after arrival in the 
postoperative care unit (PACU). Values are presented as mean ± SD. *P < 0.05, when comparing the remifentanil group with the control group 
and the pregabalin-remifentanil group.202 www.ekja.org
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the study and the postoperative sedation scores did not 
differ among the three groups (Table 4). None of the patients 
complained about the occurrence of delayed pain and any side 
effects on the first and third month after discharge from the 
hospital.
Discussion
    The results of the present investigation showed that intra-
operative remifentanil infusion during propofol anesthesia 
increased the fentanyl titration dose required to achieve 
satisfactory analgesia, and it increased the pain score. This 
phenomenon was transient and it occurred in the early post-
operative period. The preoperative orally administrated 
pregabalin 150 mg prevented fentanyl overconsumption and it 
reduced the higher pain intensity induced by remifentanil.
    The possible explanation for the larger fentanyl titration 
dose and higher pain score in the remifentanil group 
compared to that in control group would be the development 
of acute tolerance or postinfusion hyperalgesia. Guignard et 
al. [5] reported that a large dose of intraoperatively infused 
remifentanil (0.3 μg/kg/min) caused acute opioid tolerance 
and hyperalgesia. Joly et al. [6] found that a large dose of 
intraoperative remifentanil (0.4 μg/kg/min) increased the peri-
incisional wound hyperalgesia and allodynia to stimulation with 
von Frey hair. Our study differed according to two points. First, 
the remifentanil infusion rate was lower than that of the above 
mentioned studies. The remifentanil-induced pronociceptive 
effect seems to be dose dependent [8], but it has been previously 
documented that a low dose of remifentanil infusion (0.1 μg/
kg/min) could cause acute tolerance [7]. Second, the fentanyl 
requirement and pain score were increased only during the 
early postoperative period and any delayed hyperalgesia did 
not occur.
    Many drugs have been tried to attenuate or prevent the 
expression of opioid-induced tolerance and hyperalgesia 
[10,17], including gabapentinoids [15,16]. Van Elstraete et al. 
[16] suggested that the short-term use of systemic fentanyl in 
rats induced a delayed and sustained hyperalgesia, and that 
intraperitoneal and intrathecal gabapentin prevented this 
phenomenon. Gilron et al. [15] also found that gabapentin 
not only potentiated morphine’s antinociceptive effect in 
morphine tolerant rats, but it also attenuated the development 
Table 4. Mean Arterial Pressure, Heart Rate and Ramsey Sedation Score
Variable Control (n = 20) Remifentanil (n = 20) Pregabalin-Remifentanil (n = 20)
Mean arterial pressure (mmHg)
    At arrival in the PACU
    2 h
    3 h
    6 h
    24 h
    48 h
Heart rate (beats/min)
    At arrival in the PACU
    2 h
    3 h
    6 h
    24 h
    48 h
Sedation score (1/2/3/4/5/6)
    At arrival in the PACU
    2 h
    3 h
    6 h
    24 h
    48 h
93.1 ± 12.5
91.7 ± 12.6
89.6 ± 10.1
89.9 ± 9.8
83.9 ± 20.9
83.7 ± 9.7
61.7 ± 13.2
71.5 ± 12.6
71.7 ± 12.7
70.1 ± 10.4
71.8 ± 7.8
74.4 ± 6.7
3/0/12/5/0/0
0/15/4/1/0/0
0/16/4/0/0/0
17/3/0/0/0/0
0/17/3/0/0/0
17/3/0/0/0/0
102.9 ± 15.7
97.7 ± 11.5
95.6 ± 13.2
97.1 ± 11.8
90.9 ± 8.7
87.7 ± 9.0
67.8 ± 10.7
70.1 ± 9.6
68.8 ± 8.5
71.9 ± 10.9
71.7 ± 7.9
7.3.4 ± 7.8
2/3/10/5/0/0
2/15/3/0/0/0
1/17/2/0/0/0
18/2/0/0/0/0
1/17/2/0/0/0
19/1/0/0/0/0
97.0 ± 17.7
89.8 ± 10.5
91.1 ± 11.8
90.0 ± 11.0
93.4 ± 22.6
83.8 ± 12.6
71.5 ± 15.0
71.5 ± 10.5
70.8 ± 9.8
75.2 ± 12.9
72.3 ± 9.5
73.0 ± 9.9
1/1/12/6/0/0
0/17/3/0/0/0
0/18/2/0/0/0
18/2/0/0/0/0
0/19/1/0/0/0
19/1/0/0/0/0
Values are presented as mean ± SD or the number of patients. PACU: postanesthetic care unit.  
Table 3. Incidence of Side Effects
Side effect
Control
(n = 20)
Remifentanil 
(n = 20)
Pregabalin-
Remifentanil
(n = 20)
Somnolence
Headache
Nausea
Vomiting
Dizziness
Dry mouth
Pruritus
Swelling of limbs
0
0
1
0
1
2
0
0
0
1
4
0
1
1
1
0
2
1
4
0
1
0
0
0
Values are presented as the number of patients.203 www.ekja.org
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of morphine tolerance. Pregabalin probably has the same 
cellular mechanism of action as that of gabapentin, but 
pregabalin has a more favorable pharmacokinetic profile [11]. 
This suggests that pregabalin may be useful in patients with 
pain sensitization induced by opioids. Although there were no 
significant differences between the three groups for the fentanyl 
consumption by PCA in our study, the fentanyl titration dose 
and the postoperative pain score in the pregabalin-remifentanil 
group were significantly lower than those of the remifentanil 
group, and they were comparable to those of the control group 
in the immediate postoperative period. A possible explanation 
would be that the postoperative pain was controlled by titration 
of fentanyl in the PACU until the verbal rating pain score was 
less than 2, and this was followed by PCA. The total fentanyl 
consumption in the pregabalin-remifentanil group during the 
2 h postoperative period was also significantly lower than that 
of the remifentanil group. So the results could be explained by 
the modulatory effect of pregabalin on the pronociceptive effect 
induced by remifentanil.
    The exact mechanisms that may account for the opioid-
induced pronociceptive effect remain to be unraveled. Multiple 
central and peripheral pathways and mechanisms have been 
studied, including the sensitization of the primary afferent 
neurons [18], translocation and activation of protein kinase C 
[19], production of nitric oxide [9], the activation of N-methyl-
D-aspartate (NMDA) receptors [20], the enhanced production 
and release of excitatory amino acids [21] and an increase of 
spinal dynorphin [22]. Pregabalin has been demonstrated to 
bind to the α2-δ auxiliary subunit of the presynaptic voltage-
gated calcium channel [23,24]. Yet this subunit has not been 
directly associated with the development of opioid tolerance 
and hyperalgesia. The underlying hypothesis is that by its 
binding to the α2-δ subunit, pregabalin inhibits the release of 
presynaptic excitatory neurotransmitters and it may oppose the 
release induced by opioid exposure.
    There has been a report showing that perioperative admini-
stration of pregabalin was associated with a higher incidence 
of dizziness, blurred vision and headache during the first 24 h 
after surgery [25], but pregabalin 150 mg did not increase any 
side effects or the recovery times in our results. Although the 
fentanyl requirement in the PACU was significantly higher in 
the remifentanil group, there were no significant differences 
of the opioid-related adverse effects, including postoperative 
nausea and vomiting (PONV). One explanation would be that 
all the patients were given an injection of IV ondansetron 4 mg 
before the end of surgery, and the anesthesia was maintained 
with propofol.
    Propofol has been reported to inhibit NMDA receptor [26], but 
it has also been reported to produce hyperalgesia through the 
activation of the γ-amino-butyric acid A (GABAA) receptor in 
the endogenous pain descending inhibition at the superspinal 
level [27]. Therefore, it is conceivable that propofol may have 
some modulatory effects on the tolerance and postinfusion 
hyperalgesia induced by opioid. Singler et al. [28] reported 
that propofol at the subhypnotic dose led to a delay and 
weakening of the antinociceptive effect after remifentanil 
infusion in human volunteers. However, they found that 
postinfusion hyperalgesia was observed even after remifentanil 
was combined with propofol. Our results also showed that 
remifentanil infusion during propofol anesthesia caused pain 
sensitization in the early postoperative period. However, since 
our study did not evaluate the effect of propofol on opioid-
induced pronociception, no conclusion can be derived and 
future studies on this are needed.
    In summary, we found that an intraoperative remifentanil 
infusion that is given during propofol-based anesthesia caused 
a larger analgesic requirement to achieve satisfactory analgesia 
and a higher pain score in the early postoperative period. We 
also found that preemptive treatment with pregabalin prevented 
the pain sensitization induced by remifentanil. This information 
suggests that pregabalin given as premedication will be able to 
suppress the development of the pain sensitization processes 
induced by remifentanil and it may be a useful adjunctive 
agent for the management of acute postoperative pain when an 
intraoperative remifentanil infusion is required. Further studies 
are necessary to investigate the optimal dose and to explain the 
mechanisms of action of pregabalin on opioid-induced pain 
sensitization.
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